Medical Cannabis in 2026: Separating Scientific Fact from Public Friction

In my clinical practice spanning internal medicine and geriatric rehabilitation, I am increasingly positioned at the intersection of “wellness trends” and “clinical evidence.” Perhaps no topic generates more complex patient inquiries in 2026 than medical cannabis. From patients in Alicante seeking relief from chronic joint stiffness to Overseas Filipino Workers (OFWs) struggling with high-stress-induced insomnia, the prevailing public sentiment is that cannabis is a “natural,” low-risk panacea for almost any ailment.

However, as a physician dedicated to Geroscience and the preservation of Functional Reserve, I have always cautioned that “natural” is not a synonym for “safe” or “effective.” A major analysis led by UCLA Health, published in JAMA in late 2025 and widely adopted as a clinical baseline in early 2026, has issued a sobering reality check. After reviewing over 2,500 scientific papers published since 2010, the researchers found a massive “evidence gap.” While public enthusiasm for cannabis is at an all-time high, rigorous scientific support remains remarkably narrow.

1. The 2026 UCLA Review: An Evidence-Based Reality Check

The study, led by Dr. Michael Hsu of the UCLA Health Department of Psychiatry and Biobehavioral Sciences, is one of the most comprehensive “meta-reviews” ever conducted. It prioritized over 120 high-quality studies based on sample size, recency, and relevance to the current market of high-potency products.

The study highlights a persistent discrepancy between belief and biology. While roughly 27% of adults in North America report using cannabis for medical purposes, the actual clinical data supporting these uses is often “shaky” or entirely non-existent.

The “Proven” Benefits (The Narrow List)

According to the review, clear, high-quality clinical benefits are currently limited to pharmaceutical-grade cannabinoid products (like FDA-approved medications) for a very specific set of conditions:

• Severe Pediatric Seizure Disorders: Exceptional success in treating conditions like Dravet syndrome and Lennox-Gastaut syndrome.
• Chemotherapy-Induced Nausea and Vomiting: A proven second-line treatment when standard anti-emetics (like ondansetron) have failed.
• HIV/AIDS-Related Appetite Loss: Significant evidence for reversing the dangerous “wasting syndrome” associated with advanced HIV.
• MS-Related Spasticity: Modest evidence for the short-term use of oral cannabinoids in improving patient-reported muscle stiffness in Multiple Sclerosis.

2. The Gap: The “Big Three” (Pain, Anxiety, and Insomnia)

The most troubling finding for many patients is that the “Big Three”—the reasons for over 70% of medical cannabis use—lack the robust evidence many assume exists.

A. Chronic Pain: The “Modest” Relief

More than half of medical cannabis users seek relief from chronic pain. However, the UCLA review found that current clinical guidelines do not recommend cannabis as a first-line treatment. While some studies on neuropathic pain (nerve pain) show a ~40% increase in the odds of modest improvement, the evidence for general musculoskeletal or acute pain remains “insufficient.”

B. Anxiety: The Paradoxical Effect

For many, cannabis is used to “chill out.” Yet, the 2025/2026 data shows that high-potency cannabis is actually associated with a higher rate of generalized anxiety disorder (19.1%) compared to low-potency use (11.6%). In my practice, I often explain that while a small dose might provide short-term relief, chronic use can lead to “rebound anxiety” and a worsening of the underlying condition.

C. Insomnia: Withdrawal vs. Benefit

Sleep is a common reason for use, but clinical trials produced weak or inconclusive results. Many patients report “sleeping better” on cannabis, but researchers suggest this may actually be the suppression of withdrawal symptoms rather than a genuine improvement in sleep architecture. When users stop, they experience a “rebound insomnia,” which reinforces the false belief that they “need” cannabis to sleep.

3. The Hidden Risks: High Potency and the Aging Body

As a specialist in Sarcopenia y Vitalidad, my primary concern is the preservation of the heart, the brain, and the muscles. The 2025 JAMA review identified significant risks that are often ignored in the “natural wellness” narrative.

The Cardiovascular Ceiling

The analysis revealed that daily consumption, especially of inhaled or high-potency products, is linked to a doubling of the risk of cardiovascular death.

• Acute Triggers: Inhaling cannabis can act as a trigger for Myocardial Infarction (heart attack) within the first hour of use, with a relative risk of 4.8.
• Stroke Risk: Daily use was associated with a 20-40% increase in the risk of ischemic stroke, likely due to the effect of THC on endothelial function and heart rhythm.

The Psychosis Threshold

Long-term data from adolescents and young adults showed that high-potency cannabis (>10% THC) was associated with a 12.4% rate of psychotic symptoms, nearly double that of low-potency users. This is a vital concern for families and clinicians alike, as the “natural” label often blinds users to these profound psychiatric risks.

Cannabis Use Disorder (CUD)

Perhaps most surprising was the rate of addiction. Roughly 29% of medical cannabis users met the criteria for Cannabis Use Disorder. Unlike prescription drugs with fixed doses, dispensary cannabis is often unregulated at the federal level, leading to inconsistent dosing and a higher risk of dependence.

4. The “Aging Patient” (Sarcopenia and Cognition)

In our Sarcopenia y Vitalidad programs, we emphasize the “Functional Reserve.” For my seniors in Alicante or the Philippines, the introduction of medical cannabis carries a high “risk-to-reward” ratio.

• Dizziness and Falls: THC-containing products can cause orthostatic hypotension (a sudden drop in blood pressure when standing), leading to falls and fractures. In the elderly, a single hip fracture can be the end of independence.
• Cognitive Clouding: Long-term use can impair memory and executive function. For a patient already worried about early dementia, adding a psychoactive compound can “muddle” the clinical picture and accelerate cognitive decline.
• Muscle Interaction: While some claim cannabis helps with muscle pain, there is no evidence that it improves muscle function. In fact, inducing sedation may lead to decreased physical activity, which accelerates Sarcopenia (muscle wasting).

5. Global Perspectives: OFWs and the Expat Community

Navigating medical cannabis requires a culturally informed clinical lens, especially for the communities I serve.

• In Spain (Alicante & Costa Blanca): With a more relaxed view on social use, many retirees may inadvertently mix cannabis with medications for blood pressure or anticoagulation (blood thinners). This review proves that such combinations can significantly increase their stroke and heart attack risk.
• In the Philippines: While the legal landscape for medical cannabis is evolving, many seek out “unregulated” or “black market” oils. The UCLA study warns that these products often contain pesticides, heavy metals, or mold, which can cause devastating pulmonary and metabolic damage.

6. The “SCREEN” Approach: Clinical Guidance for 2026

If you are considering medical cannabis, I recommend a structured “SCREEN” approach to ensure your safety:

How I Can Help You Navigate Evidence-Based Wellness

We are entering an era where “standard advice” is being replaced by “precision geroscience.” I am here to help you integrate these 2026 breakthroughs into a lifestyle that protects your future self.

Online Medical Consultations (Philippines & Global)

For the Filipino community and OFWs worldwide, I provide 24/7 secure, HIPAA-compliant consultations to review your wellness choices.

• Medication Interaction Audit: Checking if CBD or THC will interfere with your blood pressure, heart, or diabetes medications.
• Risk Screening: Evaluating your family history for cardiovascular and psychiatric vulnerabilities.
• Longevity Planning: Finding proven, science-backed alternatives for sleep and pain management that don’t compromise your heart health.

BOOK YOUR CONSULTATION ON SERIOUSMD

Geriatric Rehab & Anti-Aging (Alicante & Costa Blanca, Spain)

In the Valencian region, we help you achieve “Autonomía y Confort” through movement and proven medical protocols, not through unverified trends.

Visit our local sites: Puente Costa Blanca | puentecostablanca.es

Our Specialized Services in Spain:

• Sarcopenia y Vitalidad: Progressive Resistance Training (PRT) programs that manage pain through natural, muscle-building endorphins—safely.
• Neuro-Functional Training: Stability and balance drills that are a safer alternative to the sedating effects of cannabis.
• Autonomía y Confort: Managing the transition of aging with a focus on clinical evidence, independence, and long-term vitality.

Final Thoughts

The 2025 UCLA review, published in JAMA in late 2025, is a victory for patient safety. It reminds us that “natural” does not automatically mean “effective” or “risk-free.” While cannabis may eventually yield more proven therapeutic uses as research matures, in 2026, we must follow the clinical evidence, not the public hype.

My priority is to ensure that your path to vitality is built on a foundation of scientific truth, protecting your heart, brain, and future independence.

Dr. Marie Gabrielle A. Laguna, MSc, M.D., FPCP, FDip (Geriatric Rehab, UK) Internal Medicine Specialist | Geriatric Rehab Expert